|
|
ASPPR |
|
Vaxjo ID |
492 |
|
Vaccine Adjuvant Name |
ASPPR |
|
Adjuvant VO ID |
VO_0005769
|
|
Description |
truncated portion of the Ov-Asp-1 that induces mixed Th1/Th2 response |
|
Stage of Development |
Research |
|
Location Licensed |
China |
|
Host Species for Testing |
Mouse |
|
Components |
residues 10–153 of Ov-ASP-1 |
|
Molecular Weight |
16 kDa |
|
Storage |
-70C |
|
Preparation |
E. coli codon-optimized cDNA was synthesized and inserted into the pQE30 expression vector, ASPPR was then purified by Ni-NTA chromotography |
|
Function |
Type: microbial derivative vaccine adjuvant. Target Receptor: Toll-like receptor 2 (TLR2) | Toll-like receptor 4 (TLR4). Induces Th1/Th2 mixed immune profile. TLR2 and TLR4 activation on APCs |
| References |
Guo et al., 2015: Guo J, Yang Y, Xiao W, Sun W, Yu H, Du L, Lustigman S, Jiang S, Kou Z, Zhou Y. A truncated fragment of Ov-ASP-1 consisting of the core pathogenesis-related-1 (PR-1) domain maintains adjuvanticity as the full-length protein. Vaccine. 2015; 33(16); 1974-1980. [PubMed: 25736195].
|
|
